Nature Communications (Sep 2023)
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment
- Yufeng Wang,
- David L. Drum,
- Ruochuan Sun,
- Yida Zhang,
- Feng Chen,
- Fengfei Sun,
- Emre Dal,
- Ling Yu,
- Jingyu Jia,
- Shahrzad Arya,
- Lin Jia,
- Song Fan,
- Steven J. Isakoff,
- Allison M. Kehlmann,
- Gianpietro Dotti,
- Fubao Liu,
- Hui Zheng,
- Cristina R. Ferrone,
- Alphonse G. Taghian,
- Albert B. DeLeo,
- Marco Ventin,
- Giulia Cattaneo,
- Yongxiang Li,
- Youssef Jounaidi,
- Peigen Huang,
- Cristina Maccalli,
- Hanyu Zhang,
- Cheng Wang,
- Jibing Yang,
- Genevieve M. Boland,
- Ruslan I. Sadreyev,
- LaiPing Wong,
- Soldano Ferrone,
- Xinhui Wang
Affiliations
- Yufeng Wang
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- David L. Drum
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Ruochuan Sun
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Yida Zhang
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Feng Chen
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Fengfei Sun
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Emre Dal
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Ling Yu
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Jingyu Jia
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Shahrzad Arya
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Lin Jia
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Song Fan
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Steven J. Isakoff
- Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center
- Allison M. Kehlmann
- Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center
- Gianpietro Dotti
- Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina
- Fubao Liu
- Department of Hepatobiliary & Pancreatic Surgery and Liver Transplantation, Anhui Medical University
- Hui Zheng
- Biostatistics Center, Massachusetts General Hospital, Harvard Medical School
- Cristina R. Ferrone
- Department of Surgery, Cedars-Sinai Medical Center
- Alphonse G. Taghian
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School
- Albert B. DeLeo
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Marco Ventin
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Giulia Cattaneo
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Yongxiang Li
- Department of Gastrointestinal Surgery and General Surgery, First Affiliated Hospital of Anhui Medical University
- Youssef Jounaidi
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School
- Peigen Huang
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School
- Cristina Maccalli
- Research Department, Sidra Medicine
- Hanyu Zhang
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Cheng Wang
- Vincent Center for Reproductive Biology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School
- Jibing Yang
- Center for Comparative Medicine, Massachusetts General Hospital, Harvard Medical School
- Genevieve M. Boland
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Ruslan I. Sadreyev
- Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School
- LaiPing Wong
- Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School
- Soldano Ferrone
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- Xinhui Wang
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-023-41282-x
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 17
Abstract
Abstract The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumors is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquire early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion. Tumors stressed by DSF/Cu and IR also reprogram and reverse the immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells of healthy donors or metastatic female breast cancer patients, induce robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a promising therapy for solid tumors.